OTCMKTS:PTIX - Protagenic Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.00 0.00 (0.00 %) (As of 05/19/2019 10:28 AM ET)Previous Close$2.00Today's Range$2.00 - $2.0052-Week Range$1.25 - $2.50Volume3 shsAverage Volume7 shsMarket Capitalization$20.52 millionP/E RatioN/ADividend YieldN/ABeta-8.8 ProfileChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Protagenic Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics to treat central nervous system disorders. Its lead drug candidate is PT00114, which is in clinical proof-of-concept studies for the treatment-resistant depression and/or post-traumatic stress disorder. The company is based in New York, New York. Receive PTIX News and Ratings via Email Sign-up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Business services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PTIX Previous Symbol CUSIPN/A CIK1022899 Webwww.protagenic.com Phone212-994-8200Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-50.00Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-2,560,000.00 Net MarginsN/A Return on Equity-3,446.47% Return on Assets-315.73%Miscellaneous EmployeesN/A Outstanding Shares10,260,000Market Cap$20.52 million Next Earnings Date5/21/2019 (Estimated) OptionableNot Optionable Protagenic Therapeutics (OTCMKTS:PTIX) Frequently Asked Questions What is Protagenic Therapeutics' stock symbol? Protagenic Therapeutics trades on the OTCMKTS under the ticker symbol "PTIX." How were Protagenic Therapeutics' earnings last quarter? Protagenic Therapeutics Inc (OTCMKTS:PTIX) posted its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.06) earnings per share for the quarter. View Protagenic Therapeutics' Earnings History. When is Protagenic Therapeutics' next earnings date? Protagenic Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Protagenic Therapeutics. Has Protagenic Therapeutics been receiving favorable news coverage? News headlines about PTIX stock have been trending positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Protagenic Therapeutics earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. Who are some of Protagenic Therapeutics' key competitors? Some companies that are related to Protagenic Therapeutics include PFSweb (PFSW), Research Solutions (RSSS), ALJ Regional (ALJJ), Kingold Jewelry (KGJI), OmniComm Systems (OMCM), DynTek (DYNE), Sito Mobile (SITO), BSQUARE (BSQR), Weyland Tech (WEYL), QuoteMedia (QMCI), SPAR Group (SGRP), Dale Jarrett Racing Adventure (TVMD), SilverSun Technologies (SSNT), China Recycling Energy (CREG) and China Techfaith Wireless Comm. Tech. (CNTF). What other stocks do shareholders of Protagenic Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protagenic Therapeutics investors own include Acasti Pharma (ACST), Amyris (AMRS), Ariad Pharmaceuticals (ARIA), Astrotech (ASTC), Athersys (ATHX), Avanir Pharmaceuticals (AVNR), China Auto Logistics (CALI), Chelsea Therapeutics International (CHTP), Neuralstem (CUR) and CytRx (CYTR). Who are Protagenic Therapeutics' key executives? Protagenic Therapeutics' management team includes the folowing people: Dr. Garo H. Armen, Co-Founder & Exec. Chairman (Age 66)Dr. Alexander K. Arrow C.F.A., M.D., CFA, CFO, Compliance Officer & Sec. (Age 48)Dr. Dalia Barsyte, Chief Technology OfficerDr. David A. Lovejoy, Chief Scientific Officer How do I buy shares of Protagenic Therapeutics? Shares of PTIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Protagenic Therapeutics' stock price today? One share of PTIX stock can currently be purchased for approximately $2.00. How big of a company is Protagenic Therapeutics? Protagenic Therapeutics has a market capitalization of $20.52 million. What is Protagenic Therapeutics' official website? The official website for Protagenic Therapeutics is http://www.protagenic.com. How can I contact Protagenic Therapeutics? Protagenic Therapeutics' mailing address is 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010. The biotechnology company can be reached via phone at 212-994-8200 or via email at [email protected] MarketBeat Community Rating for Protagenic Therapeutics (OTCMKTS PTIX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 44 (Vote Outperform)Underperform Votes: 46 (Vote Underperform)Total Votes: 90MarketBeat's community ratings are surveys of what our community members think about Protagenic Therapeutics and other stocks. Vote "Outperform" if you believe PTIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: 52-Week High/Low Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.